Email Us
Call Us
AUSTIN, Texas – December 26, 2016 – Altogen in vivo delivery technology is cited in Nature Medicine research identifying a long noncoding RNA as an epigenetic checkpoint in cardiac hypertrophy, work that demonstrated the platform’s utility well beyond oncology. Cardiac tissue is among the more demanding targets for systemic nucleic acid delivery. Reaching it reproducibly, at a dose sufficient to modulate a regulatory transcript and produce a measurable phenotype, is a meaningful technical result — and it is the kind of result that matters to sponsors developing therapies for cardiovascular, metabolic, and fibrotic disease.
Altogen Labs applies the same capability across its non-oncology preclinical portfolio. In addition to cancer research, the company conducts preclinical studies in inflammation, immunology, neurodegenerative disease, pain, infectious disease, diabetes, obesity, and metabolic disorders, supported by in vivo toxicology, biodistribution and imaging, gene expression analysis, and tissue-targeted delivery services.Study designs accommodate intravenous, intraperitoneal, intratumoral, intramuscular, subcutaneous, oral gavage, intranasal, intratracheal, topical, and continuous infusion routes, using micro-injection techniques and pump-controlled delivery. Endpoints include target mRNA quantification by RT-PCR, protein expression by automated capillary Western and ELISA, histopathology, immunohistochemistry, hematology, and full statistical treatment of all collected data. For programs requiring stable genetic modification rather than transient knockdown, Altogen Labs develops stable cell lines in 28 days, including overexpression lines, RNAi knockdown lines, and tetracycline-inducible knockdown systems.
All studies are performed by experienced scientists in the company’s GLP-compliant, IACUC-regulated Austin, Texas facility. Sponsors retain full ownership of resulting intellectual property.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research and biology CRO services to pharmaceutical, biotechnology, and academic institutions worldwide, with a large collection of validated xenograft models and extensive experience in efficacy xenograft and safety toxicology studies.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com
Source citation: Wang Z, et al., “The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy,” Nature Medicine, 2016;22:1131–1139